We are live on
!
Find out more
Alnylam Pharmaceuticals
ALNY
ALNY
356 hedge funds and large institutions have $15.8B invested in Alnylam Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 125 increasing their positions, 129 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
3% less repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 129
5% less capital invested
Capital invested by funds: $16.5B → $15.8B (-$744M)
7% less call options, than puts
Call options by funds: $121M | Put options by funds: $131M
3.68% less ownership
Funds ownership: 97.24% → 93.55% (-3.7%)
5% less funds holding
Funds holding: 374 → 356 (-18)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
35% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 49
Holders
356
Holders Change
-18
Holders Change %
-4.81%
% of All Funds
7.18%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.14%
New
32
Increased
125
Reduced
129
Closed
49
Calls
$121M
Puts
$131M
Net Calls
-$9.8M
Net Calls Change
-$52.2M
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$86.1M |
| 2 |
Goldman Sachs
New York
|
-$70.7M |
| 3 |
SPC
Slate Path Capital
New York
|
-$52.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$52.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.5M |
